Dr. Steven J. Greenberg



Steven J. Greenberg, M.D.

Steven J. Greenberg, M.D. serves as Senior Medical Director, Clinical Development, Global Pharmaceutical Research Development at Abbott Biotherapeutics/Abbott. In addition, he serves as clinical lead for the Daclizumab Multiple Sclerosis full development program. Prior to joining Abbott, Dr. Greenberg was Senior Medical Director, Global Clinical Development, Neurodegenerative Diseases at Merck Serono from 2007-2011, where he was responsible for the Oral Cladribine Tablets Multiple Sclerosis full development program, leading to the registration of the first oral treatment in relapsing-remitting multiple sclerosis. From 2003-2007, Dr. Greenberg served as Medical Director, Medical Affairs at Ortho-McNeil Janssen SA/Johnson & Johnson, where he was responsible for the development and oversight of the acute migraine (Axert) and migraine prevention (Topomax) clinical programs. Earlier in his career, Dr. Greenberg was a principal investigator in basic research, studying pathogenic mechanisms of autoimmune diseases, molecular immunology and gene transfer technology. He has published over 75 scientific articles in immunology, molecular biology, neuro-oncology, migraine, and multiple sclerosis, and he co-authored a book on the molecular diagnostics of infectious diseases.

Dr. Greenberg received his Bachelors Degree from Colgate University in New York, and Masters Degree in Microbiology and Immunology from Duke University in North Carolina and Medical Degree from the State University of New York, (SUNY) Downstate Medical Center. He completed residency training in Internal Medicine at Maimonides Medical Center in New York and in Neurology at Duke University, and completed a post-doctoral fellowship at the National Institutes of Health. He served as Chairman of the Department of Neurology at Roswell Park Cancer Center, was an Associate Professor at SUNY Buffalo, and the Director of the Neuro-Immunology Clinic at Jacobs MS Center in New York.